Treatment of Patients with Factor VIII and IX Inhibitors

Inga Marie Nilsson; Erik Berntorp; Christian Freiburghaus

doi:10.1055/s-0038-1646159

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1993; 70(01): 056-059
DOI: 10.1055/s-0038-1646159

State-of-the-Art Lecture

Hemophilia

Schattauer GmbH Stuttgart

Treatment of Patients with Factor VIII and IX Inhibitors

Inga Marie Nilsson

Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Malmö, and Excorim AB, Lund, SWEDEN

,

Erik Berntorp

Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Malmö, and Excorim AB, Lund, SWEDEN

,

Christian Freiburghaus

Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Malmö, and Excorim AB, Lund, SWEDEN

› Author Affiliations

Abstract

PDF Download

PDF (1266 kb)

References

References
1 Nilsson IM, Hedner U. Immunosuppressive treatment in hemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol 1976; 16: 369-82
2 Lusher JM, Shapiro SS, Palascak JE. et al.: Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies for factor VIII. A multicenter trial. N Engl J Med 1980; 303: 421-25
3 Sjamsoedin LJM, Heijnen L, Mauser-Bunshcoten EP. et al.: The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A randomised double-blind clinical trial. N Engl J Med 1981; 305: 717-21
4 Hedner U, Glazer S, Pingel K. et al Successful use of recombinant factor VIIa in a patient with severe hemophilia A during synovectomy. Lancet 1988; 2: 1193
5 Macik BG, Hohneker J, Roberts HR. et al.: Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor. Am J Hematol 1989; 32: 232-34
6 Birch K, Glazer S, Feldstedt M, Hedner U. Clinical results obtained so far with recombinant FVIIa. XX Int Congr World Fed Hemophilia, Athens. 1992 (abstract 160)
7 Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 1988; 69: 491-97
8 Gomperts E, Lawrence J, Liu SL. et al.: Safety and efficacy studies of recombinant tissue factor. Thromb Haemostas 1991; 65: 677
9 Kernoff PBA, Thomas ND, Lilley PA. et al.: Clinical experience with polyelectrolyte fractionated porcine factor VIII concentrate in the treatment of haemophiliacs with antibodies for factor VIII. Blood 1984; 63: 31-41
10 Nilsson IM, Sundqvist SB, Freiburghaus C. Extracorporeal protein A-Sepharose and specific affinity chromatography for removal of antibodies. In: Factor VIII Inhibitors; AR Liss, New York: 1991. pp. 225-41
11 Gjörstrup P, Berntorp E, Larsson L, Nilsson IM. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption. Vox Sang 1991; 61: 244-50
12 Nilsson IM. The management of hemophilia patients with inhibitors. Transfusion Med Rev 1992; 6: 285-93
13 Shapiro SS. Antibodies to blood coagulation factors. Clin Haematol 1979; 2: 207-14
14 Hultin MB, Shapiro SS, Bowman HS. et al.: Immunosuppressive therapy of factor VIII inhibitors. Blood 1976; 48: 95-108
15 Sultan Y, Kazatchkine MD, Maisonneuve O, Nydegger UR. Antiidiotypic suppression of autoantibodies to factor VIII (anti-hemo-philic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 1: 765-68
16 Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. In: Factor VIII Inhibitors. Hoyer LW. (ed). AR Liss; New York: 1984. pp. 181-95
17 Brackmann HH. 16 years experience with the immuntolerance induction in hemophilia patients at the Bonn Hemophilia Center. XX Int Congr World Fed Hemophilia, Athens. 1992 (abstract 12)
18 Mauser-Bunschoten EP, Nilsson IM, Kasper CK. Immune tolerance, a 1990 approach. In: Hemophilia and von Willebrand's Disease in the 1990s. Lusher JM, Kessler CM. (eds) Elsevier Science; New York: 1991. pp. 265-69
19 Aznar JA, Jorquera JI, Pieró A. et al.: The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in hemophilia A. Thromb Haemostas 1984; 51: 217-21
20 Ewing NP, Sanders NL, Dietrich SL. et al.: Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65-68
21 Nilsson IM, Sundqvist SB, Ljung R. et al.: Suppression of secondary antibody by intravenous immunoglobulin in a patient with hemophilia B and antibodies. Scand J Haematol 1983; 30: 458-64
22 Nilsson IM, Berntorp E, Zettervall O. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci USA 1986; 83: 169-73
23 Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50
24 Nilsson IM, Berntorp E, Zettervall O, Dahlbäck B. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. Blood 1990; 75: 378-83